Already a member? Sign in
Ritonavir, a protease inhibitor is used for the treatment of HIV infection; should always be used as part of a multidrug regimen (at least three antiretroviral agents); may be used as a pharmacokinetic "booster" for other protease inhibitors
| Purpose | # of patients |
# of patients with evaluations
Efficacy
|
Major | Moderate | Slight | None | Can’t tell |
|---|---|---|---|---|---|---|---|
| HIV (Human Immunodeficiency Virus) | 216 | 60 |
|
|
|
|
|
| Increase effect of another treatment | 12 | 4 |
|
|
|
||
| Other | 8 | 2 |
|
|
|||
| Support immune health | 8 | 1 |
|
||||
| Fatigue | 2 | 0 | |||||
| Pain | 1 | 0 |
See all 240 patients currently taking Ritonavir
Mouse over the table for more information
Commonly reported side effects, conditions, and hospitalizations associated with Ritonavir
| Diarrhea | 10 | |
|---|---|---|
| Flatulence | 5 | |
| Cramps in stomach | 5 | |
| Lightheadedness | 3 | |
| Tiredness | 3 | |
| Sickness | 3 | |
| See all 17 reported side effects ▼ | ||
Frequently reported dosages based on patients currently taking Ritonavir. See all 13 dosages ►
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
| Side effects too severe | 13 | ||
| Other | 12 | ||
| Doctor's advice | 12 | ||
| Course of treatment ended | 4 | ||
| Personal research | 4 | ||
| Did not seem to work | 3 | ||
| Expense | 2 | ||
| Not indicated | 2 | ||
| Change in health plan coverage | 1 |
Adherence
Taking treatment as prescribed
Adherence of Ritonavir
Always |
54 | 86% |
|
|---|---|---|---|
Usually |
5 | 8% |
|
Sometimes |
2 | 3% |
|
Never |
2 | 3% |
|
Burden
Difficulty being on treatment
Burden of Ritonavir
Very |
2 | 3% |
|
|---|---|---|---|
Somewhat |
8 | 13% |
|
A little |
14 | 22% |
|
Not at all |
39 | 62% |
|
Cost
Paid out of pocket
Cost of Ritonavir
$200+ |
3 | 6% |
|
|---|---|---|---|
$100-199 |
0 | 0% |
|
$50-99 |
6 | 13% |
|
$25-49 |
4 | 9% |
|
< $25 |
34 | 72% |
|
See more information, including instructions, precautions, side effects, and interactions.
Report created on February 08, 2012.